查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1590811

胃食道逆流疾病治疗药物市场：按类型、药物类别、应用划分 - 全球预测 2025-2030

Gastroesophageal Reflux Disease Therapeutics Market by Type (Branded, Generics), Drug Class (Aminosalicylates, Anti-Diarrheal, Anti-Emetics), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年胃食道逆流症治疗市值为58.5亿美元，预计2024年将达61.4亿美元，复合年增长率为5.01%，到2030年将达到82.4亿美元，预计将达到1000万美元。

胃食道逆流症 (GERD) 治疗药物市场重点在于可用于治疗 GERD 的治疗方案，GERD 是一种慢性消化系统疾病，胃酸和胆汁会刺激食道内壁。这项市场需求是由肥胖、饮酒增加、吸烟和老龄化等生活方式因素导致的胃食道逆流的流行所推动的，这些因素共同推动了对有效治疗性介入的需求。这些治疗应用包括质子帮浦阻断剂、H2 受体拮抗剂、抗酸剂和促动力药，每种药物都针对不同的机制来缓解 GERD 症状。最终用途包括医院、专科诊所和居家医疗，促进治疗方法的广泛采用。就市场洞察而言，医疗保健支出的增加、对胃食道逆流的认识不断提高以及药物开发的进步是推动成长的关键因素。此外，新型药物输送系统和个人化医疗方法的引入也带来了潜在的商机。儘管有这些正面影响，但市场仍面临挑战，例如严格的监管核准、高昂的治疗成本以及与长期使用某些药物相关的副作用。微创手术、生物分解性支架和以患者为中心的行动医疗应用等领域的创新有可能进一步改善结果。此外，探索益生菌和营养食品作为补充治疗方法可以提供新的收益来源。 GERD 治疗市场呈现出不断变化的形势，由于全球消费者意识的不断增强和医疗保健投资的增加，该市场有望实现增长。企业应专注于扩大研发活动并建立策略伙伴关係关係，以解决未满足的需求并提高竞争力。然而，也必须考虑遵守严格监管标准和提高可及性的经济有效的策略。为了抓住这个充满活力的行业的新机会，保持对消费者趋势和技术进步的敏感度非常重要。

主要市场统计
基准年[2023] 58.5亿美元
预测年份 [2024] 61.4亿美元
预测年份 [2030] 82.4亿美元
复合年增长率（%） 5.01%

市场动态：揭示快速发展的胃食道逆流药物市场的关键市场洞察

胃食道逆流药物市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 胃食道逆流患者病率上升
    • 建立不健康的生活方式和饮食习惯
    • 质子帮浦抑制剂的使用增加
  • 市场限制因素
    • 与 GERD 药物相关的副作用
  • 市场机会
    • 药厂加大研发投入
    • GERD治疗器械在微创手术中的普及
  • 市场挑战
    • 自然疗法的替代品

波特五力：驾驭胃食道逆流药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解胃食道逆流药物市场的外部影响

外部宏观环境因素在塑造胃食道逆流疾病治疗药物市场的表现动态中发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解胃食道逆流症治疗药物市场的竞争状况

对胃食道逆流症治疗药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵胃食道逆流药物市场供应商的绩效评估

FPNV定位矩阵是评估胃食道逆流症治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘胃食道逆流症治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对胃食道逆流症治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 胃食道逆流患者病率增加
      • 采取不健康的生活方式和饮食习惯
      • 质子帮浦阻断剂的使用增加
    • 抑制因素
      • 与胃食道逆流药物相关的副作用
    • 机会
      • 药厂加大研发投入
      • GERD 装置在微创手术中变得流行
    • 任务
      • 自然疗法的替代品
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章胃食道逆流症治疗药物市场：依类型

  • 品牌
  • 非专利的

第七章依药物类别分類的胃食道逆流症治疗药物市场

  • 氨基胺基
  • 止泻
  • 止吐药
  • 生技药品/生物相似药
  • 消化酵素
  • H2拮抗剂
  • 泻药
  • 质子帮浦抑制剂

第八章胃食道逆流症治疗药物市场：依应用分类

  • 克隆氏症
  • 胃食道逆流症
  • 溃疡性大肠炎

第九章北美及南美胃食道逆流症治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太胃食道逆流症治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲胃食道逆流症治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
  • 战略分析和建议

公司名单

  • Aurobindo Pharma Limited
  • Cadila Pharmaceuticals Limited
  • CHEPLAPHARM Arzneimittel GmbH
  • Daewoong Pharmaceutical Co., Ltd
  • Eisai Co., Ltd.
  • EndoStim, Inc.
  • GlaxoSmithKline PLC
  • Jeil Pharmaceutical Co., Ltd.
  • Novartis AG
  • Reckitt Benckiser Group PLC
  • SFJ Pharmaceuticals Group
  • SRS Life Sciences Pte. Ltd.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Co., Ltd.
  • Teva Pharmaceuticals Industries Limited
Product Code: MRR-AD36CD897D13

The Gastroesophageal Reflux Disease Therapeutics Market was valued at USD 5.85 billion in 2023, expected to reach USD 6.14 billion in 2024, and is projected to grow at a CAGR of 5.01%, to USD 8.24 billion by 2030.

The Gastroesophageal Reflux Disease (GERD) Therapeutics market focuses on the treatment options available for managing GERD, a chronic digestive disorder where stomach acid or bile irritates the food pipe lining. The necessity of this market stems from the prevalence of GERD due to lifestyle factors like obesity, increased consumption of alcohol, smoking, and aging, which collectively increase the demand for effective therapeutic interventions. The application of these therapeutics spans proton pump inhibitors, H2 receptor antagonists, antacids, and prokinetics, each targeting different mechanisms to alleviate GERD symptoms. End-use segments include hospitals, specialty clinics, and homecare settings, facilitating widespread availability of treatments. As for market insights, rising healthcare expenditure, increased awareness about GERD, and advancements in drug development are key factors driving growth. Additionally, the incorporation of novel drug delivery systems and personalized medicine approaches present potential opportunities. Despite these positive influences, the market faces challenges such as stringent regulatory approvals, high treatment costs, and the side effects associated with long-term use of certain medications. Innovating in areas like minimally invasive surgical procedures, biodegradable stents, and patient-centric mobile health applications could further enhance therapeutic outcomes. Additionally, exploring probiotics and dietary supplements as complementary treatments can provide new revenue streams. The GERD therapeutics market showcases an evolving landscape poised for growth as consumer awareness and investment in healthcare rise globally. Companies should focus on expanding their R&D activities and forming strategic partnerships to address unmet needs and enhance their competitive edge. However, they must also navigate compliance with stringent regulatory standards and consider cost-effective strategies to increase accessibility. With its dynamic nature, staying attuned to consumer trends and technological advancements will be crucial for capturing emerging opportunities in this sector.

KEY MARKET STATISTICS
Base Year [2023] USD 5.85 billion
Estimated Year [2024] USD 6.14 billion
Forecast Year [2030] USD 8.24 billion
CAGR (%) 5.01%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gastroesophageal Reflux Disease Therapeutics Market

The Gastroesophageal Reflux Disease Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of gastroesophageal reflux diseases
    • Adoption of unhealthy lifestyle and eating habits
    • Increasing use of proton pump inhibitors
  • Market Restraints
    • Side effects related to the drugs of GERD
  • Market Opportunities
    • Increasing investment by pharma companies in R&D
    • GERD devices gaining traction for minimally invasive procedures
  • Market Challenges
    • Alternatives of natural remedies

Porter's Five Forces: A Strategic Tool for Navigating the Gastroesophageal Reflux Disease Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gastroesophageal Reflux Disease Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gastroesophageal Reflux Disease Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gastroesophageal Reflux Disease Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gastroesophageal Reflux Disease Therapeutics Market

A detailed market share analysis in the Gastroesophageal Reflux Disease Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gastroesophageal Reflux Disease Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gastroesophageal Reflux Disease Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gastroesophageal Reflux Disease Therapeutics Market

A strategic analysis of the Gastroesophageal Reflux Disease Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gastroesophageal Reflux Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Aurobindo Pharma Limited, Cadila Pharmaceuticals Limited, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co., Ltd, Eisai Co., Ltd., EndoStim, Inc., GlaxoSmithKline PLC, Jeil Pharmaceutical Co., Ltd., Novartis AG, Reckitt Benckiser Group PLC, SFJ Pharmaceuticals Group, SRS Life Sciences Pte. Ltd., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceuticals Industries Limited.

Market Segmentation & Coverage

This research report categorizes the Gastroesophageal Reflux Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Branded and Generics.
  • Based on Drug Class, market is studied across Aminosalicylates, Anti-Diarrheal, Anti-Emetics, Biologics/Biosimilar, Digestive enzymes, H2 Antagonists, Laxatives, and Proton Pump Inhibitors.
  • Based on Application, market is studied across Crohn's Disease, GERD, and Ulcerative Colitis.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of gastroesophageal reflux diseases
      • 5.1.1.2. Adoption of unhealthy lifestyle and eating habits
      • 5.1.1.3. Increasing use of proton pump inhibitors
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects related to the drugs of GERD
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investment by pharma companies in R&D
      • 5.1.3.2. GERD devices gaining traction for minimally invasive procedures
    • 5.1.4. Challenges
      • 5.1.4.1. Alternatives of natural remedies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Gastroesophageal Reflux Disease Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Branded
  • 6.3. Generics

7. Gastroesophageal Reflux Disease Therapeutics Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Aminosalicylates
  • 7.3. Anti-Diarrheal
  • 7.4. Anti-Emetics
  • 7.5. Biologics/Biosimilar
  • 7.6. Digestive enzymes
  • 7.7. H2 Antagonists
  • 7.8. Laxatives
  • 7.9. Proton Pump Inhibitors

8. Gastroesophageal Reflux Disease Therapeutics Market, by Application

  • 8.1. Introduction
  • 8.2. Crohn's Disease
  • 8.3. GERD
  • 8.4. Ulcerative Colitis

9. Americas Gastroesophageal Reflux Disease Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Gastroesophageal Reflux Disease Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aurobindo Pharma Limited
  • 2. Cadila Pharmaceuticals Limited
  • 3. CHEPLAPHARM Arzneimittel GmbH
  • 4. Daewoong Pharmaceutical Co., Ltd
  • 5. Eisai Co., Ltd.
  • 6. EndoStim, Inc.
  • 7. GlaxoSmithKline PLC
  • 8. Jeil Pharmaceutical Co., Ltd.
  • 9. Novartis AG
  • 10. Reckitt Benckiser Group PLC
  • 11. SFJ Pharmaceuticals Group
  • 12. SRS Life Sciences Pte. Ltd.
  • 13. Sun Pharmaceutical Industries Limited
  • 14. Takeda Pharmaceutical Co., Ltd.
  • 15. Teva Pharmaceuticals Industries Limited

LIST OF FIGURES

  • FIGURE 1. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTI-DIARRHEAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTI-EMETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS/BIOSIMILAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DIGESTIVE ENZYMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GERD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 151. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023